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Background
An estimated 63,920 cases of kidney cancer will occur in
the USA in 2015, and about 13,860 deaths will occur.
The incidences of kidney cancer has steadily increased
by 2-4% each year. Currently high dose IL (Interleukin)-
2, VEGF (vascular endothelial growth factor) inhibitors,
and mTOR (mammalian target of rapamycin) inhibitors
are often used to treat metastatic kidney cancer, but all
of the above treatments lead to a median survival
between 1-2 years.
Therefore, there is a large role for discovering new
drugs against new molecules that drive cancer growth.
Although the understanding of biology leading to better
treatments will likely require analysis of metastatic
tumor tissue, most studies have only analyzed the pri-
mary tumor. We studied both primary and metastatic
tumors from FFPE tissue to identify new kinase genes
expressed in metastatic tumors compared to primary
kidney tumors. These data may enable the design of
new drugs, since it is relatively easier to design kinase
inhibitors.
Methods
A total of 54 samples of primary tumor, adjacent normal
kidney, and metastatic tumor from 18 patients were
available. RNA from FFPE tissue samples was analyzed
using Nanostring technology for expression of 519 kinase
genes. This technology is robust for studying gene
expression, even from FFPE tissue. The data was analyzed
using the nCounter platform (NanoString Technologies,
Seattle, WA). Data quality check and normalization was
performed prior to analysis. Over-expression was defined
as at least 2-fold elevation compared to reference genes.
Descriptive analysis and unsupervised cluster analysis
were applied. This study has approval of Institutional
Review Board.
Results
There is a cluster of kinase genes over expressed in
metastasis, but not in normal and primary tumor. ROS1,
EPHA3, PLK1 and CDK1 were among the top 10 genes
over-expressed in metastases compared to either pri-
mary tumor or normal kidney. All of the top kinases
genes over-expressed in metastases in our study are
known to drive growth, survival and metastasis of tumor
cells. There are 8 unique genes over-expressed only in
metastasis compared to primary tumor (CDK7, ICK,
KDR, LTK, OBSCN, PRKCH, RIPK3 and SGK110).
Some genes were under-expressed in tumors compared
to normal kidney, suggesting that some kinase genes
could protect against tumor growth.
Conclusions
We identified genes only overexpressed in metastatic kid-
ney tumor tissue, which may represent drivers of metasta-
sis and targets for new drugs. Confirmation of findings is
required before clinical trials of new drugs.
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